Evidence map›Paper›PMID 40237805›Full record

ReviewIntensive care medicine2025

Contemporary review of critical illness following allogeneic hematopoietic stem cell transplant in adults.

Laveena Munshi, Guillaume Dumas, Bruno Ferreryro, Cristina Gutierrez, Boris Böll, Pedro Castro, Sanjay Chawla, Matteo Di Nardo, Antoine Lafarge, Colleen McEvoy and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Intensive care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Laveena MunshiDepartment of Medicine, Interdepartmental Division of Critical Care Medicine, Sinai Health System, University of Toronto, Toronto, Canada. Laveena.munshi@sinaihealth.ca.ORCID 0000-0003-0551-9533
Guillaume DumasService de Médecine Intensive-Réanimation, CHU Grenoble-AlpesUniversité Grenoble-Alpes, INSERM U1042-HP2, Grenoble, France.
Bruno FerreryroDepartment of Medicine, Interdepartmental Division of Critical Care Medicine, Sinai Health System, University of Toronto, Toronto, Canada.
Cristina GutierrezDepartment of Critical Care, The University of Texas M.D. Anderson Cancer Center, Houston, USA.
Boris BöllIntensive Care Medicine and Hematology-Oncology, University Hospital Cologne, Cologne, Germany.
Pedro CastroMedical Intensive Care Unit, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Sanjay ChawlaCritical Care Medicine Service, Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Matteo Di NardoPediatric Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Antoine LafargeMédecine Intensive Et Réanimation, APHP, Saint-Louis Hospital and Paris University, Paris, France.
Colleen McEvoyDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, USA.
Djamel MokartDepartment of Anesthesiology and Intensive Care Unit, Institut Paoli-Calmettes, Marseille, France.
Antonio Paulo NassarDepartment of Intensive Care, A.C. Camargo Cancer Center, São Paulo, Brazil.
Judith NelsonMemorial Hospital, Weill Cornell Medical College, New York, USA.
Frédéric PèneUniversité Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, DMU Réanimation-Urgences, Service de Médecine Intensive Réanimation, Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Peter SchellongowskiIntensive Care Unit 13i2, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Elie AzoulayMédecine Intensive Et Réanimation, APHP, Saint-Louis Hospital and Paris University, Paris, France.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Significant advancements have been made in the care of the allogeneic hematopoietic stem cell (HCT) recipient. However, they remain one of the most vulnerable groups of patients who may be admitted to the ICU. On the one hand, they have been administered treatment with the goal of achieving cure for their underlying disease, yet their unique immunocompromised trajectory and treatment-associated toxicities continue to challenge the intensivist from a diagnostic and management perspective. While infectious disease, allogeneic HCT and critical care research have improved outcomes, there remain significant areas to advance critical care management to further increase the likelihood of bridging to an acceptable quality of life. This review focuses on care of the critically ill patient undergoing allogeneic HCT for hematologic malignancies, critical care conditions that may arise, contemporary practices in their management, and areas to focus future research.

Indexed as

Critical CareCritical IllnessHematologic NeoplasmsHematopoietic Stem Cell TransplantationAdultHumansIntensive Care UnitsTransplantation, HomologousAllogeneic hematopoietic stem cell transplantHematologic malignancyImmunocompromised

Identifiers

PMID40237805
PMCPMC12411934

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.